EA026750B1 - КРИСТАЛЛИЧЕСКИЙ (1R,4R)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН - Google Patents

КРИСТАЛЛИЧЕСКИЙ (1R,4R)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН Download PDF

Info

Publication number
EA026750B1
EA026750B1 EA201400120A EA201400120A EA026750B1 EA 026750 B1 EA026750 B1 EA 026750B1 EA 201400120 A EA201400120 A EA 201400120A EA 201400120 A EA201400120 A EA 201400120A EA 026750 B1 EA026750 B1 EA 026750B1
Authority
EA
Eurasian Patent Office
Prior art keywords
approximately
crystalline form
dimethyl
fluoro
pyrano
Prior art date
Application number
EA201400120A
Other languages
English (en)
Russian (ru)
Other versions
EA201400120A1 (ru
Inventor
Михаэль Грусс
Штефан Клуге
Штефан Прюс
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Publication of EA201400120A1 publication Critical patent/EA201400120A1/ru
Publication of EA026750B1 publication Critical patent/EA026750B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
EA201400120A 2011-07-08 2012-07-06 КРИСТАЛЛИЧЕСКИЙ (1R,4R)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН EA026750B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11005587 2011-07-08
PCT/EP2012/002839 WO2013007361A1 (en) 2011-07-08 2012-07-06 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Publications (2)

Publication Number Publication Date
EA201400120A1 EA201400120A1 (ru) 2014-06-30
EA026750B1 true EA026750B1 (ru) 2017-05-31

Family

ID=46717800

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400120A EA026750B1 (ru) 2011-07-08 2012-07-06 КРИСТАЛЛИЧЕСКИЙ (1R,4R)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН

Country Status (23)

Country Link
US (2) US8618156B2 (https=)
EP (2) EP3235821B1 (https=)
JP (2) JP6276689B2 (https=)
CN (2) CN106939005A (https=)
AR (1) AR087081A1 (https=)
AU (2) AU2012283449B2 (https=)
BR (1) BR112014000358A2 (https=)
CA (1) CA2841032C (https=)
CY (1) CY1120525T1 (https=)
DK (2) DK2729470T3 (https=)
EA (1) EA026750B1 (https=)
ES (1) ES2641299T3 (https=)
HR (1) HRP20170968T1 (https=)
HU (1) HUE033043T2 (https=)
IL (1) IL230331B (https=)
LT (1) LT2729470T (https=)
MX (1) MX2014000297A (https=)
PL (1) PL2729470T3 (https=)
PT (1) PT2729470T (https=)
RS (1) RS56343B1 (https=)
SI (1) SI2729470T1 (https=)
TW (1) TWI585092B (https=)
WO (1) WO2013007361A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106939005A (zh) * 2011-07-08 2017-07-11 格吕伦塔尔有限公司 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺
CA2974578C (en) 2015-01-23 2020-11-17 Grunenthal Gmbh Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
ES2713960T3 (es) 2015-02-02 2019-05-24 Ratiopharm Gmbh Composición que comprende cebranopadol en forma disuelta
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定
WO2020233588A1 (zh) * 2019-05-21 2020-11-26 江苏众强药业有限公司 曲前列尼尔钠盐新晶型及制备方法
CN112254496A (zh) * 2020-09-25 2021-01-22 榆林学院 一种煤泥收集装置
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
JP2026506102A (ja) 2023-02-15 2026-02-20 アドニューリス・セラピューティクス・インコーポレーテッド 疼痛緩和に有用なレジメンおよび組成物
WO2026035694A1 (en) 2024-08-05 2026-02-12 Adneuris Therapeutics, Inc. Cebranopadol useful for preventing or reducing opioid induced respiratory depression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043967A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische cyclohexan-derivate
WO2006108565A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spirocyclishe cyclohexanderivate zur behandlung von substanzabhängigkeit
WO2008009415A2 (de) * 2006-07-18 2008-01-24 Grünenthal GmbH 4-heteroaryl-substituierte 1-aminocyclohexan-1- und cyclohexen-1-derivate mit wirkung auf das opiod rezeptor system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
PE20131096A1 (es) * 2010-08-04 2013-10-10 Gruenenthal Chemie Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico
CN106939005A (zh) * 2011-07-08 2017-07-11 格吕伦塔尔有限公司 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043967A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische cyclohexan-derivate
WO2006108565A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spirocyclishe cyclohexanderivate zur behandlung von substanzabhängigkeit
WO2008009415A2 (de) * 2006-07-18 2008-01-24 Grünenthal GmbH 4-heteroaryl-substituierte 1-aminocyclohexan-1- und cyclohexen-1-derivate mit wirkung auf das opiod rezeptor system

Also Published As

Publication number Publication date
WO2013007361A8 (en) 2013-04-04
HUE033043T2 (hu) 2017-11-28
WO2013007361A9 (en) 2013-12-27
EP3235821A1 (en) 2017-10-25
AU2017204572B2 (en) 2018-05-24
JP2017081981A (ja) 2017-05-18
JP6559165B2 (ja) 2019-08-14
AU2017204572A1 (en) 2017-07-27
AU2012283449A8 (en) 2014-03-27
AU2012283449B2 (en) 2017-04-06
JP2014518226A (ja) 2014-07-28
CN103649094B (zh) 2017-05-24
MX2014000297A (es) 2014-01-31
CN106939005A (zh) 2017-07-11
DK3235821T3 (da) 2020-04-20
CY1120525T1 (el) 2019-07-10
PL2729470T3 (pl) 2017-11-30
WO2013007361A1 (en) 2013-01-17
LT2729470T (lt) 2017-08-25
US20130012563A1 (en) 2013-01-10
PT2729470T (pt) 2017-10-02
US8618156B2 (en) 2013-12-31
ES2641299T3 (es) 2017-11-08
CN103649094A (zh) 2014-03-19
AU2012283449A1 (en) 2014-02-20
EP2729470B1 (en) 2017-06-21
AR087081A1 (es) 2014-02-12
TW201311694A (zh) 2013-03-16
US20130231381A1 (en) 2013-09-05
RS56343B1 (sr) 2017-12-29
JP6276689B2 (ja) 2018-02-07
HRP20170968T1 (hr) 2017-09-22
EP3235821B1 (en) 2020-04-08
BR112014000358A2 (pt) 2017-01-10
EP2729470A1 (en) 2014-05-14
CA2841032A1 (en) 2013-01-17
SI2729470T1 (sl) 2017-10-30
CA2841032C (en) 2020-12-15
EA201400120A1 (ru) 2014-06-30
TWI585092B (zh) 2017-06-01
IL230331B (en) 2018-11-29
DK2729470T3 (en) 2017-09-11
US8765800B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
EA026750B1 (ru) КРИСТАЛЛИЧЕСКИЙ (1R,4R)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН
JP2022140559A (ja) Rad1901-2hclの多形性形態
US12410189B2 (en) Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production
EP1919893A2 (en) Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
WO2011089401A1 (en) Crystalline forms of a purine derivative
CN103476770A (zh) 新的阿法替尼盐和多晶型物
US8614245B2 (en) Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
CA2858762C (en) Solid forms of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine hydrochloride
WO2012156384A1 (en) Novel crystalline salts of asenapine
CN108473507A (zh) 噻吩并嘧啶化合物的结晶形式
TW202016099A (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
WO2013087591A1 (en) Solid forms of (1r,4r)-6'-fluoro-(n,n-dimethyl)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
RU2779119C2 (ru) Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения
CN121419965A (zh) 吡啶氮氧化合物的盐型、共晶及其制备方法和应用
KR20220047822A (ko) 피리미디노 디아제핀 유도체의 결정질 형태
HK1195900A (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
HK1195900B (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU